Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (01349) Releases January 2026 Monthly Return

Bulletin Express

Feb 02

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (stock code: 01349) announced that, as of January 31, 2026, its total registered share capital remained RMB 103,657,210. The company reported 326,000,000 H shares and 710,572,100 A shares, each with a par value of RMB 0.1, with no changes from the previous month.

The announcement confirmed that the public float requirement for its H shares was met in accordance with the minimum threshold of 25%. There were no share repurchases, treasury shares, or other movements in issued shares during the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1122005133"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122005133\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122005133?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122005133","market":"hk","top_or_hot":-1,"title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (01349) Releases January 2026 Monthly Return","media":"Bulletin Express","content":"<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (stock code: 01349) announced that, as of January 31, 2026, its total registered share capital remained RMB 103,657,210. The company reported 326,000,000 H shares and 710,572,100 A shares, each with a par value of RMB 0.1, with no changes from the previous month.</p>\n<p>The announcement confirmed that the public float requirement for its H shares was met in accordance with the minimum threshold of 25%. There were no share repurchases, treasury shares, or other movements in issued shares during the reporting period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (01349) Releases January 2026 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fudan-Zhangjiang Bio-Pharmaceutical (01349) Releases January 2026 Monthly Return\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-02 18:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (stock code: 01349) announced that, as of January 31, 2026, its total registered share capital remained RMB 103,657,210. The company reported 326,000,000 H shares and 710,572,100 A shares, each with a par value of RMB 0.1, with no changes from the previous month.</p>\n<p>The announcement confirmed that the public float requirement for its H shares was met in accordance with the minimum threshold of 25%. There were no share repurchases, treasury shares, or other movements in issued shares during the reporting period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01349","symbol_name":"复旦张江","start_time":0,"source_url":"","article_id":"1122005133","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122005133","pubTimestamp":1770027979,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (stock code: 01349) announced that, as of January 31, 2026, its total registered share capital remained RMB 103,657,210. The company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01349":"复旦张江"},"translate_title":"上海复旦张江生物制药(01349)发布2026年1月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01349":1},"content_text":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (stock code: 01349) announced that, as of January 31, 2026, its total registered share capital remained RMB 103,657,210. The company reported 326,000,000 H shares and 710,572,100 A shares, each with a par value of RMB 0.1, with no changes from the previous month.\nThe announcement confirmed that the public float requirement for its H shares was met in accordance with the minimum threshold of 25%. There were no share repurchases, treasury shares, or other movements in issued shares during the reporting period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}